As has recently been published on the Karolinska Institutet in Sweden’s website, a new study led by professor Per-Olof Berggren and his colleagues shows that obesogenic diet–induced damage to the blood vessels of pancreatic islets may be long-lasting and resistant to reversal, even after returning to a healthy diet. The findings have been published in …
Aktieägarna i Biocrine AB kallas härmed till årsstämma torsdagen den 26 juni 2025 kl 11:00 Plats: Rolf Luft Forskningscentrum, Anna Steckséns gata 53, Solna (översta våningsplanet). Avstämningsdag: 2025-06-17 Sista anmälningsdag: 2025-06-23
Aktieägarna i Biocrine AB kallas härmed till årsstämma måndagen den 17 juni 2024 kl 15:00 Plats: Redeye AB, Mäster Samuelsgatan 42, våning 10 sal Dialog, Stockholm. Avstämningsdag: 2024-06-07 Sista anmälningsdag: 2024-06-12 Mer information angående årsstämman finns HÄR.
Newly published article in Scientific Reports (www.nature.com/scientificreports) about the development of a novel platform for intravital 3D imaging of RT2 tumours to facilitate real-time studies of cancer progression. Full access to article is found HERE.
Per-Olof Berggren has been elected to The National Academy of Medicine The National Academy of Medicine announced today the election of 70 U.S. members and 9 international members during its annual meeting. Election to the Academy is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have …
Professor Per-Olof Berggren has received 4 major distinctions during 2012: Alex Hirsch from Karolinska Institutet, Wallenberg Scholars, The Novo Nordisk Foundation Advanced Grant and Kroc Lecture at Boston University Medical Center. Professor Berggren’s distinctions are for the following achievements: Axel Hirsch Prize from Karolinska Institutet. The prize is for scientific achievements, which are potentially of major significance to the treatment of …
Biocrine’s CEO Professor PO Berggren was interviewed by NyTeknik, Swedish leading technology and IT newspaper. Treating diabetes with transplanted insulin-producing islets of Langerhans was the main subject of the discussion. Transplantation into the eye is a novel method developed by Prof Berggren’s research group. So far, the procedure has been thoroughly tested in mice leading …
www.biocrine.se is live Our company web site www.biocrine.com is now launched. We will be looking forward to your feedback on info@biocrine.se. With best regards, The Biocrine team
On the 28th of October 2011, Biocrine was featured as one of the prominent life science companies on the 92nd annual meeting of IVA. In an interview for IVA, Biocrine’s CEO Per-Olof Berggren talked about the main focus of the research; understanding of how a healthy insulin producing beta cell works, …